Hepta Bio
PrivateLast Round
Seed
Nov 5, 2025
Total Funding Raised
$6.7M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Hepta Bio operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Seed round in November 2025.
Hepta Bio is a biotechnology company that develops a liquid biopsy and AI platform to read the cell-free DNA epigenome and detect organ-specific signals of chronic disease, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical AI, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hepta Bio Comparables
Compare Hepta Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AGED Diagnostics | 89% | |
| Glycotest, Inc. | 75% | |
| Senseera | 71% |
For institutional investors. Book with your work email.
Hepta Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hepta Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SeaX Ventures | Seed |
| AME Cloud Ventures | Seed |
| Alumni Ventures | Seed |
| Felicis Ventures | Seed |
| Illumina Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
LiquidTransformer analyzes liver biology from blood draws, detailed at NeurIPS 2026.
- Nov 5, 2026
Paper on LiquidTransformer AI architecture accepted at NeurIPS 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 5, 2026
Hepta attends the 2026 Conference on Neural Information Processing Systems (NeurIPS), where its accepted paper explains how LiquidTransformer addresses chronic-disease AI architecture needs.
For institutional investors. Book with your work email.
Hepta Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hepta Bio's valuation, stock price, and market status.
Is Hepta Bio a public or private company?
Hepta Bio is a private company.
What is the current stock price of Hepta Bio?
Hepta Bio is a private company, so its shares have no public market price. Caplight tracks Hepta Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hepta Bio worth (valuation)?
Valuation information for Hepta Bio is not publicly available.
Can I buy Hepta Bio stock?
Hepta Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hepta Bio's last funding round?
Hepta Bio's most recent funding round was Seed on November 5, 2025.
Who are the main investors in Hepta Bio?
Key investors in Hepta Bio include Felicis Ventures, Illumina Ventures.
Will Hepta Bio IPO soon?
No public IPO plans have been announced for Hepta Bio.
How can I track Hepta Bio secondary market activity?
Caplight tracks bids, offers, and trades in Hepta Bio's shares on secondary markets.